« FDA approves device to maintain blood flow during artery bypass | Main | FDA Approvals - FDA informs Novartis of extension to US regulatory review period »

FDA modifies boxed warning for pulmonary arterial hypertension drug Letairis


FDA modifies boxed warning for pulmonary arterial hypertension drug Letairis
The U.S. Food and Drug Administration today announced that monthly liver enzyme tests are no longer required for those taking Letairis tablets (ambrisentan), used to treat high blood pressure in the vessels that carry blood to the lungs (pulmonary arterial hypertension, or PAH).
 

©2006 FDA-News.com. All rights reserved.